| 2026-09-11 09:15 |
8-K |
["2.01"] |
merger agreement |
0.99
|
Eli Lilly acquisition of AtaiBeckley completed Sept 11, 2026 for $6.75/share plus contingent CVRs. |
SEC · detail |
| 2026-09-08 17:09 |
8-K |
["5.07"] |
merger agreement |
0.98
|
AtaiBeckley stockholders approved merger with Eli Lilly; closing expected September 11, 2026. |
SEC · detail |
| 2026-08-31 16:38 |
8-K |
["8.01"] |
merger agreement |
0.98
|
Definitive merger agreement with Eli Lilly; Hart-Scott-Rodino clearance obtained; regulatory approvals progressing. |
SEC · detail |
| 2026-08-10 06:09 |
DEFM14A |
|
merger agreement |
1.00
|
DEFM14A: Eli Lilly acquiring AtaiBeckley for $6.75/share + $2.50 CVR; stockholder vote Sept 8, 2026. |
SEC · detail |
| 2026-07-29 21:46 |
PREM14A |
|
merger agreement |
0.99
|
Definitive PREM14A proxy for Eli Lilly acquisition of AtaiBeckley at $6.75/share plus CVR, approved by board. |
SEC · detail |
| 2026-07-16 07:27 |
8-K |
["1.01"] |
merger agreement |
0.99
|
AtaiBeckley Inc. entered into definitive merger agreement with Eli Lilly on July 15, 2026 for $6.75/share plus CVRs. |
SEC · detail |
| 2026-06-08 17:00 |
8-K |
["5.07"] |
other |
0.00
|
Routine annual meeting filing with director elections and auditor ratification; no M&A signals. |
SEC · detail |
| 2026-06-03 07:52 |
8-K |
["7.01"] |
other |
0.05
|
Routine 8-K disclosing investor conference participation and program updates; no M&A signals. |
SEC · detail |
| 2026-05-12 08:17 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with no M&A signals or strategic transaction indicators. |
SEC · detail |